Literature DB >> 22146109

Prediction of human plasma concentration-time profiles of monoclonal antibodies from monkey data by a species-invariant time method.

Masataka Oitate1, Shintaro Nakayama, Takashi Ito, Atsushi Kurihara, Noriko Okudaira, Takashi Izumi.   

Abstract

We have previously reported that human total body clearance (CL) and steady-state volume of distribution (Vss) of monoclonal antibodies (mAbs) could be predicted reasonably well from monkey data alone using simple allometry with scaling exponents of 0.79 and 1.12 (for soluble targets), and 0.96 and 1.00 (for membrane-bound targets). In the present study, to predict the plasma concentration-time profiles of mAbs in humans, we employed simple dose-normalization and species-invariant time methods (elementary Dedrick plot and complex Dedrick plot), based on the monkey data and the scaling exponents we previously determined. The results demonstrated that the species-invariant time methods were able to provide higher accuracy of prediction than simple dose-normalization, regardless of the type of target antigens (soluble or membrane-bound). The accuracy between elementary Dedrick plot and complex Dedrick plot was nearly equivalent. The predicted human CL and Vss using species-invariant time methods were within mostly 2-fold differences from the observed values. The prediction not only of pharmacokinetic (PK) parameters but also of the plasma concentration-time profile in humans can serve as guidelines for better planning of clinical studies on mAbs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22146109     DOI: 10.2133/dmpk.dmpk-11-sh-059

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  11 in total

1.  Combination of cassette-dosing and microsampling for reduced animal usage for antibody pharmacokinetics in cynomolgus monkeys, wild-type mice, and human FcRn transgenic mice.

Authors:  Miho Nagayasu; Kazuhisa Ozeki
Journal:  Pharm Res       Date:  2021-03-29       Impact factor: 4.200

2.  Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition.

Authors:  Aman P Singh; Wojciech Krzyzanski; Steven W Martin; Gregory Weber; Alison Betts; Alaa Ahmad; Anson Abraham; Anup Zutshi; John Lin; Pratap Singh
Journal:  AAPS J       Date:  2014-12-03       Impact factor: 4.009

Review 3.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

4.  Simple Approach to Accurately Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies after Subcutaneous Injection in Humans.

Authors:  Kenta Haraya; Tatsuhiko Tachibana
Journal:  Clin Pharmacokinet       Date:  2021-01       Impact factor: 6.447

5.  A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans.

Authors:  Konstantinos Biliouris; Ivan Nestorov; Himanshu Naik; David Dai; Guangqing Xiao; Qin Wang; Alex Pellerin; Dania Rabah; Lawrence J Lesko; Mirjam N Trame
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-10-30       Impact factor: 2.745

6.  Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development.

Authors:  Meric Ovacik; Kedan Lin
Journal:  Clin Transl Sci       Date:  2018-08-07       Impact factor: 4.689

7.  Pharmacokinetic comparison of a diverse panel of non-targeting human antibodies as matched IgG1 and IgG2 isotypes in rodents and non-human primates.

Authors:  Kenneth W Walker; Hossein Salimi-Moosavi; Gregory E Arnold; Qing Chen; Marcus Soto; Frederick W Jacobsen; John Hui
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

8.  Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5).

Authors:  Jennifer Ahlberg; Craig Giragossian; Hua Li; Maria Myzithras; Ernie Raymond; Gary Caviness; Christine Grimaldi; Su-Ellen Brown; Rocio Perez; Danlin Yang; Rachel Kroe-Barrett; David Joseph; Chandrasena Pamulapati; Kelly Coble; Peter Ruus; Joseph R Woska; Rajkumar Ganesan; Steven Hansel; M Lamine Mbow
Journal:  MAbs       Date:  2019-06-04       Impact factor: 5.857

Review 9.  Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings.

Authors:  Eva Germovsek; Ming Cheng; Craig Giragossian
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

10.  Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC.

Authors:  Isabel Figueroa; Doug Leipold; Steve Leong; Bing Zheng; Montserrat Triguero-Carrasco; Aimee Fourie-O'Donohue; Katherine R Kozak; Keyang Xu; Melissa Schutten; Hong Wang; Andrew G Polson; Amrita V Kamath
Journal:  MAbs       Date:  2018-05-18       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.